CN116528869B - 氨基杂芳基激酶抑制剂 - Google Patents

氨基杂芳基激酶抑制剂

Info

Publication number
CN116528869B
CN116528869B CN202180079929.6A CN202180079929A CN116528869B CN 116528869 B CN116528869 B CN 116528869B CN 202180079929 A CN202180079929 A CN 202180079929A CN 116528869 B CN116528869 B CN 116528869B
Authority
CN
China
Prior art keywords
optionally substituted
formula
compound
alkyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180079929.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN116528869A (zh
Inventor
成岱
丁强
何志祥
周小波
周洋
尹小航
谢泽强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anrui Biopharmaceutical Co
Original Assignee
Anrui Biomedical Technology Guangzhou Co ltd
Anrui Biopharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anrui Biomedical Technology Guangzhou Co ltd, Anrui Biopharmaceutical Co filed Critical Anrui Biomedical Technology Guangzhou Co ltd
Publication of CN116528869A publication Critical patent/CN116528869A/zh
Application granted granted Critical
Publication of CN116528869B publication Critical patent/CN116528869B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/20—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hydrogen atoms and substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D309/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Control Of El Displays (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202180079929.6A 2020-11-27 2021-11-26 氨基杂芳基激酶抑制剂 Active CN116528869B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/132454 2020-11-27
CN2020132454 2020-11-27
CNPCT/CN2021/081236 2021-03-17
CN2021081236 2021-03-17
PCT/CN2021/133429 WO2022111621A1 (en) 2020-11-27 2021-11-26 Aminoheteroaryl kinase inhibitors

Publications (2)

Publication Number Publication Date
CN116528869A CN116528869A (zh) 2023-08-01
CN116528869B true CN116528869B (zh) 2026-04-14

Family

ID=81753779

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180079929.6A Active CN116528869B (zh) 2020-11-27 2021-11-26 氨基杂芳基激酶抑制剂
CN202280077473.4A Pending CN118475562A (zh) 2020-11-27 2022-11-23 氨基杂芳基激酶抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202280077473.4A Pending CN118475562A (zh) 2020-11-27 2022-11-23 氨基杂芳基激酶抑制剂

Country Status (10)

Country Link
US (2) US20240166635A1 (https=)
EP (2) EP4251613A4 (https=)
JP (2) JP2024506116A (https=)
KR (1) KR20230127228A (https=)
CN (2) CN116528869B (https=)
AU (3) AU2021385745C1 (https=)
CA (2) CA3202990A1 (https=)
IL (1) IL303237A (https=)
MX (1) MX2024006300A (https=)
WO (2) WO2022111621A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230127228A (ko) * 2020-11-27 2023-08-31 올오리온 테라퓨틱스 인크. 아미노헤테로아릴 키나아제 억제제
CA3207392A1 (en) * 2021-02-05 2022-08-11 Xiaoxia Yan Cdk inhibitor
EP4532473A1 (en) * 2022-05-27 2025-04-09 Allorion Therapeutics Inc. Aminoheteroaryl kinase inhibitors
EP4731620A1 (en) * 2023-06-25 2026-04-29 Allorion Therapeutics Inc Isotopologues of aminoheteroaryl kinase inhibitors and uses thereof
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers
EP4725942A1 (en) * 2024-10-09 2026-04-15 Sibylla Biotech S.p.A. Compounds active on cyclin d1 pathway and their use

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1406230A (zh) * 2000-03-01 2003-03-26 阿斯特拉曾尼卡有限公司 用作抗肿瘤药的2,4－二(杂－)芳基氨基(－氧基)－5－取代的嘧啶
CN1406231A (zh) * 2000-03-01 2003-03-26 阿斯特拉曾尼卡有限公司 嘧啶化合物
WO2003076435A1 (en) * 2002-03-09 2003-09-18 Astrazeneca Ab Pyrimidine compounds
CN1452620A (zh) * 2000-09-05 2003-10-29 阿斯特拉曾尼卡有限公司 作为细胞增生抑制剂的咪唑－5－基－2－苯胺基－嘧啶
CN1454210A (zh) * 2000-07-11 2003-11-05 阿斯特拉曾尼卡有限公司 嘧啶衍生物
CN1541208A (zh) * 2001-05-30 2004-10-27 用作细胞周期蛋白依赖性激酶抑制剂的2-苯氨基-嘧啶衍生物
CN1549813A (zh) * 2000-12-21 2004-11-24 作为血管生成调节剂的嘧啶胺
CN1633419A (zh) * 2001-05-29 2005-06-29 舍林股份公司 Cdk抑制性嘧啶化合物、其制备方法以及作为药物的应用
CN1649863A (zh) * 2002-03-09 2005-08-03 阿斯特拉曾尼卡有限公司 具有cdk抑制活性的4－(咪唑－5－基)－2－(4－磺基苯胺基)嘧啶衍生物
CN1703405A (zh) * 2001-11-01 2005-11-30 詹森药业有限公司 用作糖原合酶激酶3β抑制剂的氨基苯甲酰胺衍生物
CN1717396A (zh) * 2002-11-28 2006-01-04 舍林股份公司 Chk－、Pdk－和Akt－抑制嘧啶,其制备及作为药物的用途
CN101678215A (zh) * 2007-04-18 2010-03-24 辉瑞产品公司 用于治疗异常细胞生长的磺酰胺衍生物
CN101679440A (zh) * 2007-04-02 2010-03-24 帕劳制药股份有限公司 作为jak3抑制剂的吡咯并嘧啶衍生物
CN102224144A (zh) * 2008-10-21 2011-10-19 拜耳先灵医药股份有限公司 作为cdk抑制剂的砜取代的苯胺基嘧啶衍生物、其制备以及作为药物的用途
CN102834100A (zh) * 2010-04-01 2012-12-19 拜耳知识产权有限责任公司 新型pan-CDK抑制剂用于治疗肿瘤的用途
CN116472270A (zh) * 2021-02-05 2023-07-21 上海齐鲁制药研究中心有限公司 Cdk抑制剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003212282A1 (en) * 2002-03-11 2003-09-22 Schering Aktiengesellschaft Cdk inhibiting 2-heteroaryl pyrimidine, the production thereof, and use thereof as a medicament
US7504396B2 (en) * 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
DE102005008310A1 (de) * 2005-02-17 2006-08-24 Schering Ag Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle
WO2006122003A2 (en) * 2005-05-05 2006-11-16 Ardea Biosciences, Inc. Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv
EP2125781A2 (en) * 2006-12-20 2009-12-02 Amgen Inc. Substituted heterocycles and methods of use
NZ580671A (en) * 2007-04-16 2012-03-30 Hutchison Medipharma Entpr Ltd Pyrimidine derivatives
WO2009022171A1 (en) * 2007-08-13 2009-02-19 Astrazeneca Ab Pyridinyiioxy pyridines as alk5 inhibitors
AR074209A1 (es) * 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina utiles para el tratamiento del cancer
CN103958482B (zh) * 2011-11-29 2017-06-09 健泰科生物技术公司 作为lrrk2调节剂的氨基嘧啶衍生物
NZ629830A (en) * 2014-07-14 2015-12-24 Signal Pharm Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
CN110386901B (zh) * 2018-04-23 2022-11-25 上海医药工业研究院 含磺酰苯胺嘧啶结构的化合物及其作为抗肿瘤药物的应用
US12037323B2 (en) * 2018-05-03 2024-07-16 Bristol-Myers Squibb Company Uracil derivatives as Mer-AXL inhibitors
WO2020205560A1 (en) * 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
JP2023515629A (ja) * 2020-02-28 2023-04-13 フォチョン・バイオサイエンシーズ・リミテッド Ｃｄｋ２／４／６阻害剤としての化合物
WO2022096473A1 (en) * 2020-11-04 2022-05-12 Umicore A positive electrode active material for rechargeable batteries
KR20230127228A (ko) * 2020-11-27 2023-08-31 올오리온 테라퓨틱스 인크. 아미노헤테로아릴 키나아제 억제제

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1406230A (zh) * 2000-03-01 2003-03-26 阿斯特拉曾尼卡有限公司 用作抗肿瘤药的2,4－二(杂－)芳基氨基(－氧基)－5－取代的嘧啶
CN1406231A (zh) * 2000-03-01 2003-03-26 阿斯特拉曾尼卡有限公司 嘧啶化合物
CN1454210A (zh) * 2000-07-11 2003-11-05 阿斯特拉曾尼卡有限公司 嘧啶衍生物
CN1452620A (zh) * 2000-09-05 2003-10-29 阿斯特拉曾尼卡有限公司 作为细胞增生抑制剂的咪唑－5－基－2－苯胺基－嘧啶
CN1549813A (zh) * 2000-12-21 2004-11-24 作为血管生成调节剂的嘧啶胺
CN1633419A (zh) * 2001-05-29 2005-06-29 舍林股份公司 Cdk抑制性嘧啶化合物、其制备方法以及作为药物的应用
CN1541208A (zh) * 2001-05-30 2004-10-27 用作细胞周期蛋白依赖性激酶抑制剂的2-苯氨基-嘧啶衍生物
CN1703405A (zh) * 2001-11-01 2005-11-30 詹森药业有限公司 用作糖原合酶激酶3β抑制剂的氨基苯甲酰胺衍生物
CN1649863A (zh) * 2002-03-09 2005-08-03 阿斯特拉曾尼卡有限公司 具有cdk抑制活性的4－(咪唑－5－基)－2－(4－磺基苯胺基)嘧啶衍生物
WO2003076435A1 (en) * 2002-03-09 2003-09-18 Astrazeneca Ab Pyrimidine compounds
CN1717396A (zh) * 2002-11-28 2006-01-04 舍林股份公司 Chk－、Pdk－和Akt－抑制嘧啶,其制备及作为药物的用途
CN101679440A (zh) * 2007-04-02 2010-03-24 帕劳制药股份有限公司 作为jak3抑制剂的吡咯并嘧啶衍生物
CN101678215A (zh) * 2007-04-18 2010-03-24 辉瑞产品公司 用于治疗异常细胞生长的磺酰胺衍生物
CN102224144A (zh) * 2008-10-21 2011-10-19 拜耳先灵医药股份有限公司 作为cdk抑制剂的砜取代的苯胺基嘧啶衍生物、其制备以及作为药物的用途
CN102834100A (zh) * 2010-04-01 2012-12-19 拜耳知识产权有限责任公司 新型pan-CDK抑制剂用于治疗肿瘤的用途
CN116472270A (zh) * 2021-02-05 2023-07-21 上海齐鲁制药研究中心有限公司 Cdk抑制剂

Also Published As

Publication number Publication date
EP4436959A4 (en) 2026-02-11
CA3202990A1 (en) 2022-06-02
US20250002480A1 (en) 2025-01-02
WO2023093769A1 (en) 2023-06-01
KR20230127228A (ko) 2023-08-31
AU2025200001A1 (en) 2025-01-23
CN118475562A (zh) 2024-08-09
AU2021385745B2 (en) 2024-10-03
CA3238970A1 (en) 2023-06-01
JP2024541533A (ja) 2024-11-08
AU2022397678A1 (en) 2024-05-30
JP2024506116A (ja) 2024-02-09
EP4436959A1 (en) 2024-10-02
US20240166635A1 (en) 2024-05-23
EP4251613A1 (en) 2023-10-04
AU2021385745C1 (en) 2025-02-20
IL303237A (en) 2023-07-01
WO2022111621A1 (en) 2022-06-02
CN116528869A (zh) 2023-08-01
MX2024006300A (es) 2024-07-24
AU2021385745A9 (en) 2025-03-27
AU2021385745A1 (en) 2023-06-15
EP4251613A4 (en) 2024-11-20

Similar Documents

Publication Publication Date Title
CN116528869B (zh) 氨基杂芳基激酶抑制剂
TWI894229B (zh) 作為yap/taz-tead蛋白-蛋白相互作用抑制劑之聯芳基衍生物
KR102757890B1 (ko) 화합물, 조성물 및 방법
JP7626910B2 (ja) Ｒａｆキナーゼの阻害剤
ES2952994T3 (es) Compuestos, composiciones y métodos
JP2022520236A (ja) 化合物、組成物、及び、方法
WO2019183589A1 (en) Modulators of eukaryotic initiation factor 2
CN117177744A (zh) Cdk2抑制剂及其使用方法
CN119630652A (zh) 氨基杂芳基激酶抑制剂
JP2025508323A (ja) Ｃｄｋ４／６キナーゼの阻害薬
US20250320185A1 (en) Aminoheteroaryl kinase inhibitors
CA2631661A1 (en) Nitroimidazole compounds
JP2025534444A (ja) ホスホルアミダート化合物及びその用途
KR20240021923A (ko) Parp7 억제제 및 이의 용도
HK40092567A (zh) 氨基杂芳基激酶抑制剂
WO2023017152A1 (en) Specific small molecule inhibitors that block kmt9 methyltransferase activity and function
RU2830596C1 (ru) Биарильные производные в качестве ингибиторов белок-белкового взаимодействия yap/taz-tead
EA047452B1 (ru) Биарильные производные в качестве ингибиторов белок-белкового взаимодействия yap/taz-tead
OA22136A (en) Pyrrole compounds.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40092567

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240126

Address after: Massachusetts, USA

Applicant after: Anrui Biopharmaceutical Co.

Country or region after: U.S.A.

Address before: 9th Floor, Building 2, Laidi Innovation Technology Park, No. 188 Kaiyuan Avenue, Huangpu District, Guangzhou City, Guangdong Province, 510530

Applicant before: Anrui Biomedical Technology (Guangzhou) Co.,Ltd.

Country or region before: China

GR01 Patent grant